VivoSeq
Oncology

Lymphoblastic Lymphoma

47

Pipeline Programs↗

5

Active Trials↗

32

Companies Involved↗

Lymphoblastic Lymphoma is a moderately active landscape with 47 programs across 32 companies. The most active players are Bristol-Myers Squibb, Pfizer, Amgen. 16 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

6/100

Mech. Concentration

24/100

Completion Rate

83/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Pfizer logo

Pfizer

2 programs

Phase 2Amgen logo

Amgen

2 programs

Phase 2A

Avyxa

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

44 of 53 classified programs — the dominant modality here.

17%ALL OTHERSProtein / enzyme59%Cell therapy36%Monoclonal antibody12%

Small molecule leads; the ring shows all 53 classified programs, each share of the total. Modality classified for 100% of 53 pipeline programs.

Analysis

Trial Status

18

clinical trials

Unknown status7 · 39%
Completed5 · 28%
Recruiting3 · 17%
Not yet recruiting2 · 11%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
Recruiting·CChildren's Cancer Group, China·Phase 3·NCT05681260·200 enrolled
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Recruiting·UUniversity Hospital Muenster·Phase 3·NCT04043494·683 enrolled
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT06686108·59 enrolled
The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma
Not yet recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06434467·83 enrolled
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Not yet recruiting·Children's Oncology Group·Phase 2/3·NCT07072585·1,708 enrolled
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
Completed·MM.D. Anderson Cancer Center·N/A·NCT01099202·109 enrolled
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199017·75 enrolled
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Completed·Children's Oncology Group·Phase 3·NCT00004228·393 enrolled
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT01363817·31 enrolled
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01451515·23 enrolled
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma
Terminated·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00275106·600 enrolled
Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma
Unknown status·SSun Yat-sen University·Phase 2·NCT02396043·50 enrolled
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT05576532·30 enrolled
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
Unknown status·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1·NCT04004637·10 enrolled
Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT04916860·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)